Skip to main content
. 2014 Oct 6;10(4):342–347. doi: 10.3988/jcn.2014.10.4.342

Fig. 1.

Fig. 1

Study timelines. Study I: a single-limb safety and efficacy study. Study II: a case-control extended study. Inline graphic: time to rhEPO injection, Inline graphic: time to clinical assessment, ▵: time to measure ALSFRS-R to evaluate primary outcome. ALSFRS-R: amyotrophic lateral sclerosis Functional Rating Scale-Revised, rhEPO: recombinant human erythropoietin.